Skip to main content
Year archive

NOXOPHARM LIMITED — 2020 filings

All 148 regulatory filings released by NOXOPHARM LIMITED (NOX) in 2020, sourced directly from the official regulator.

148 Filings
2020 Period
2020 filings (148)
Filing Released Lang
Federal Government Approved Future Overseas R&D Expenditure 2 pages 215.6KB
Capital/Financing Update
2020-12-22 English
Appendix 3G 14 pages 267.4KB
Share Issue/Capital Change
2020-12-14 English
Change of Director's Interest Notice - FB 3 pages 158.4KB
Director's Dealing
2020-12-14 English
Change of Director's Interest Notice - BP 3 pages 158.8KB
Director's Dealing
2020-12-14 English
Appendix 2A 16 pages 262.0KB
Regulatory Filings
2020-12-14 English
Cleansing Notice 2 pages 214.3KB
Share Issue/Capital Change
2020-12-14 English
December Investor Webinar Recording 2 pages 231.0KB
Capital/Financing Update
2020-12-10 English
Appendix 2A 16 pages 260.4KB
Capital/Financing Update
2020-12-09 English
Cleansing Notice 2 pages 214.2KB
Share Issue/Capital Change
2020-12-09 English
Change in substantial holding 3 pages 130.6KB
Major Shareholding Notification
2020-12-09 English
Noxopharm Corporate Presentation December Investor Webinar 22 pages 7.4MB
Investor Presentation
2020-12-07 English
Pre-Clinical Breakthrough Discovery Set to Expand Pipeline 4 pages 265.4KB
Regulatory Filings
2020-12-06 English
Noxopharm December Investor Webinar Details 2 pages 204.7KB
Investor Presentation
2020-12-03 English
Noxopharm Completes A$23m Placement to Fund Clinical Studies 3 pages 228.3KB
Capital/Financing Update
2020-12-02 English
Proposed issue of Securities - NOX 5 pages 28.2KB
Capital/Financing Update
2020-12-02 English
Cleansing Statement 2 pages 216.3KB
Regulatory Filings
2020-12-02 English
Trading Halt 3 pages 296.1KB
Capital/Financing Update
2020-11-30 English
Appendix 2A 16 pages 262.2KB
Capital/Financing Update
2020-11-30 English
Lapsing of Unlisted Options 2 pages 223.5KB
Capital/Financing Update
2020-11-26 English
Change of Director's Interest Notice - PM 3 pages 158.3KB
Director's Dealing
2020-11-26 English
Further Independent Support for Veyonda as a Major I-O Drug 3 pages 241.3KB
Regulatory Filings
2020-11-17 English
Appendix 3G 13 pages 260.8KB
Share Issue/Capital Change
2020-11-17 English
Appendix 2A 16 pages 261.1KB
Capital/Financing Update
2020-11-17 English
Cleansing Notice 2 pages 214.2KB
Share Issue/Capital Change
2020-11-17 English
Change of Director's Interest Notice - GK 4 pages 164.2KB
Director's Dealing
2020-11-17 English
2020 AGM Chairman's Address 4 pages 276.3KB
AGM Information
2020-11-16 English
Noxopharm 2020 AGM Corporate Update 26 pages 7.7MB
Investor Presentation
2020-11-16 English
Noxopharm Annual General Meeting Results 4 pages 255.0KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-16 English
Independent Discovery Validates DARRT Cancer Therapy 3 pages 229.7KB
Capital/Financing Update
2020-11-12 English
Veyonda To Be Tested In Combination With Opdivo In Trial 3 pages 227.5KB
Capital/Financing Update
2020-11-08 English
NOXCOVID Study Cleared To Expand 2 pages 214.2KB
Regulatory Filings
2020-11-04 English
Dedicated Septic Shock Company Established 4 pages 235.4KB
Capital/Financing Update
2020-11-04 English
2020 Annual General Meeting Reminder 2 pages 209.9KB
AGM Information
2020-11-02 English
First Two Cohorts Enrolled in NOXCOVID Study 2 pages 203.9KB
Regulatory Filings
2020-10-25 English
Appendix 2A 16 pages 261.1KB
Capital/Financing Update
2020-10-25 English
Cleansing Notice 2 pages 216.4KB
Regulatory Filings
2020-10-25 English
Noxopharm Quarterly Activities Report & Appendix 4C 9 pages 325.6KB
Interim / Quarterly Report Q1 2021
2020-10-14 English
Notice of Annual General Meeting and Proxy Form 54 pages 4.0MB
AGM Information
2020-10-13 English
Cover Letter and Proxy Form - Annual General Meeting 8 pages 670.4KB
AGM Information
2020-10-13 English
LuPIN Study Achieves Final Patient Treatment 3 pages 229.4KB
Capital/Financing Update
2020-10-11 English
Appendix 2A 16 pages 227.7KB
Capital/Financing Update
2020-10-08 English
Cleansing Notice 2 pages 216.8KB
Regulatory Filings
2020-10-08 English
Unlisted Options Expiring 27 November 2020 2 pages 210.6KB
Capital/Financing Update
2020-10-08 English
Noxopharm CMO Discusses the NOXCOVID trial 2 pages 200.7KB
Regulatory Filings
2020-10-08 English
Noxopharm Loan Terms Amended to Benefit Company 3 pages 259.0KB
Capital/Financing Update
2020-10-05 English
First COVID-19 Patient Treated in Veyonda Study 3 pages 280.0KB
Regulatory Filings
2020-10-01 English
Noxopharm Corporate Presentation September 2020 32 pages 4.8MB
Investor Presentation
2020-09-20 English
Noxopharm Appoints US Corporate Advisory and Consulting Firm 2 pages 207.4KB
Capital/Financing Update
2020-09-17 English
Notification of Date of 2020 Annual General Meeting 2 pages 212.3KB
AGM Information
2020-09-16 English
Appendix 4G and Corporate Governance Statement 22 pages 710.6KB
Regulatory Filings
2020-09-14 English
Annual Report to shareholders 72 pages 1.9MB
Annual Report FY 2020
2020-09-14 English
Noxopharm Appoints New Chair 2 pages 203.7KB
Board/Management Information
2020-09-08 English
Global CRO To Execute DARRT-2 Prostate Cancer Study 2 pages 147.3KB
Regulatory Filings
2020-09-07 English
Veyonda COVID-19 Study Approved For Immediate Start 3 pages 196.1KB
Regulatory Filings
2020-08-31 English
Noxopharm Announces Board Changes 2 pages 148.9KB
Board/Management Information
2020-08-30 English
Appendix 4G and Corporate Governance Statement 22 pages 711.9KB
Regulatory Filings
2020-08-30 English
Appendix 4E and Audited Financial Statements FY2020 64 pages 1.3MB
Annual Report FY 2020
2020-08-30 English
Final Director's Interest Notice - ID 2 pages 122.6KB
Director's Dealing
2020-08-30 English
Noxopharm August 2020 EGM Corporate Presentation 31 pages 5.0MB
AGM Information
2020-08-13 English
Results of Meeting 3 pages 222.2KB
Declaration of Voting Results & Voting Rights Announcements
2020-08-13 English
Appendix 2A - Underwriter Options 16 pages 262.6KB
Capital/Financing Update
2020-08-13 English
Cleansing Notice 2 pages 214.0KB
Capital/Financing Update
2020-08-13 English
Appendix 2A - Shares 16 pages 261.5KB
Capital/Financing Update
2020-08-13 English
Peer-Reviewed Publication Strengthens Case For Veyonda 3 pages 226.0KB
Regulatory Filings
2020-08-10 English
Noxopharm Extraordinary General Meeting Reminder 3 pages 214.1KB
Regulatory Filings
2020-08-05 English
Noxopharm 2020 June quarter Appendix 4C & Activities Report 10 pages 413.4KB
Interim / Quarterly Report Q4 2020
2020-07-28 English
Notice of Contravention of Listing Rule 10.11 2 pages 209.5KB
Capital/Financing Update
2020-07-23 English
Change of Director's Interest Notice - FB 3 pages 224.0KB
Director's Dealing
2020-07-23 English
Noxopharm Discusses Converting Cold to Hot Cancer Tumours 1
Regulatory Filings
2020-07-22 English
Receipt of cash payment for collateral shares 2 pages 218.5KB
Capital/Financing Update
2020-07-21 English
Data Shows Idronoxil Holds Key to Problem of COLD Cancers 5 pages 376.9KB
Regulatory Filings
2020-07-19 English
Notice of Extraordinary General Meeting/Proxy Form 19 pages 977.5KB
Proxy Solicitation & Information Statement
2020-07-13 English
Letter to Shareholders - Extraordinary General Meeting 3 pages 246.6KB
Proxy Solicitation & Information Statement
2020-07-13 English
Noxopharm July 2020 Newsletter Released 7 pages 2.4MB
Investor Presentation
2020-07-13 English
Corporate Presentation for the Reach Markets Virtual Event 19 pages 918.5KB
Investor Presentation
2020-07-07 English
Ceasing to be a substantial holder 1 page 161.1KB
Major Shareholding Notification
2020-07-02 English
Change of Director's Interest Notice - FB 2 pages 225.6KB
Director's Dealing
2020-06-28 English
Noxopharm Chair Letter to Shareholders 5 pages 319.6KB
Capital/Financing Update
2020-06-21 English
Change in substantial holding 2 pages 1.1MB
Major Shareholding Notification
2020-06-21 English
Change in substantial holding - amended 2 pages 550.2KB
Major Shareholding Notification
2020-06-21 English
COVID-19 Trial Program to Commence in Europe 5 pages 232.2KB
Regulatory Filings
2020-06-18 English
Appendix 2A - options 19 pages 388.3KB
Regulatory Filings
2020-06-17 English
Appendix 2A - shares 15 pages 306.7KB
Capital/Financing Update
2020-06-17 English
Change of Director's Interest Notice - GK 4 pages 228.6KB
Director's Dealing
2020-06-17 English
Change of Director's Interest Notice - PM 3 pages 217.9KB
Director's Dealing
2020-06-17 English
Change of Director's Interest Notice - FB 2 pages 216.0KB
Director's Dealing
2020-06-17 English
Change of Director's Interest Notice - BP 3 pages 209.6KB
Director's Dealing
2020-06-17 English
Change in substantial holding 3 pages 131.1KB
Major Shareholding Notification
2020-06-17 English
Change in substantial holding 2 pages 200.8KB
Major Shareholding Notification
2020-06-17 English
Pro-rata Non-Renounceable Rights Issue Fully Allocated 2 pages 237.2KB
Capital/Financing Update
2020-06-14 English
Rights Issue Close Date 3 pages 211.4KB
Capital/Financing Update
2020-06-08 English
Webcast Overview of ASCO 2020 Annual Meeting NOX Posters 2 pages 198.0KB
Investor Presentation
2020-06-04 English
Change of Director's Interest Notice - ID 3 pages 222.8KB
Director's Dealing
2020-06-03 English
Change of Director's Interest Notice - PM 3 pages 223.8KB
Director's Dealing
2020-06-03 English
ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer 5 pages 162.5KB
Investor Presentation
2020-05-31 English
Appendix 3G Adjustment to Option Exercise Prices 13 pages 367.4KB
Share Issue/Capital Change
2020-05-31 English
Listing Rule 6.22.2 Adjustment to Option Exercise Prices 2 pages 296.5KB
Capital/Financing Update
2020-05-27 English
Proposed issue of Securities - NOX 6 pages 30.0KB
Capital/Financing Update
2020-05-21 English
Despatch of Pro Rata Entitlement Offer Documents 4 pages 335.4KB
Capital/Financing Update
2020-05-20 English
FDA allows Veyonda Pre-IND Submission for COVID-19 3 pages 284.2KB
Capital/Financing Update
2020-05-18 English
Noxopharm ASCO Abstracts Live 3 pages 231.9KB
Regulatory Filings
2020-05-13 English
$7.9 Million Fully Underwritten Entitlement Offer Announced 9 pages 277.6KB
Capital/Financing Update
2020-05-12 English
Proposed issue of Securities - NOX 8 pages 36.7KB
Capital/Financing Update
2020-05-12 English
Entitlement Offer - Letter to Eligible Shareholders 6 pages 456.0KB
Capital/Financing Update
2020-05-12 English
Entitlement Offer - Letter to Ineligible Shareholders 3 pages 394.1KB
Capital/Financing Update
2020-05-12 English
Entitlement Offer - Letter to Optionholders 4 pages 426.1KB
Capital/Financing Update
2020-05-12 English
Entitlement Offer Prospectus 47 pages 734.3KB
Capital/Financing Update
2020-05-12 English
Appendix 2A 16 pages 303.5KB
Capital/Financing Update
2020-05-12 English
Appointment of New Board Member 2 pages 198.8KB
Board/Management Information
2020-05-07 English
Initial Director's Interest Notice - FB 2 pages 146.5KB
Director's Dealing
2020-05-07 English
Trading Halt 2 pages 270.9KB
Capital/Financing Update
2020-05-06 English
Change in substantial holding 3 pages 133.3KB
Major Shareholding Notification
2020-04-30 English
Change in substantial holding 2 pages 1.7MB
Major Shareholding Notification
2020-04-30 English
Abscopal Responses Achieved in Prostate Cancer 3 pages 174.9KB
Regulatory Filings
2020-04-29 English
Noxopharm March 2020 Quarterly Report & Appendix 4C 10 pages 459.3KB
Interim / Quarterly Report Q3 2020
2020-04-29 English
Pipeline Expands With Potential New Brain Cancer Treatment 4 pages 139.7KB
Regulatory Filings
2020-04-22 English
Approval to be sought for COVID-19 Clinical Study in U.S. 5 pages 237.3KB
Regulatory Filings
2020-04-20 English
Receipt of cash payment for collateral shares 2 pages 248.2KB
Capital/Financing Update
2020-04-19 English
Noxopharm trial data to be presented at ASCO 2020 3 pages 233.7KB
Investor Presentation
2020-04-06 English
Updated Noxopharm Virtual Roadshow Corporate Presentation 21 pages 4.5MB
Investor Presentation
2020-04-01 English
Noxopharm Investigating Potential COVID-19 Treatment 5 pages 174.9KB
Capital/Financing Update
2020-03-31 English
Noxopharm Virtual Roadshow Corporate Presentation 17 pages 3.9MB
Investor Presentation
2020-03-30 English
Appointment of New Board Member 2 pages 196.4KB
Board/Management Information
2020-03-25 English
Initial Director's Interest Notice 2 pages 146.2KB
Director's Dealing
2020-03-25 English
Veyonda Awarded First Allowed Patent Application 2 pages 260.8KB
Regulatory Filings
2020-03-16 English
Veyonda Clinical Program Update and Guidance 4 pages 224.9KB
Regulatory Filings
2020-03-12 English
LuPIN Prostate Cancer Trial Fully Recruited 3 pages 220.3KB
Regulatory Filings
2020-03-02 English
Noxopharm Corporate Presentation February 2020 27 pages 1.4MB
Investor Presentation
2020-02-26 English
Half Year Accounts and Chairman Letter 23 pages 9.9MB
Interim / Quarterly Report
2020-02-24 English
FDA grants IND approval to Veyonda 2 pages 259.9KB
Regulatory Filings
2020-02-20 English
Appendix 2A 15 pages 257.8KB
Regulatory Filings
2020-02-20 English
Section 708 Certificate 2 pages 252.2KB
Capital/Financing Update
2020-02-20 English
Noxopharm Alliance With GenesisCare 4 pages 288.8KB
Regulatory Filings
2020-02-17 English
Appendix 2A 15 pages 260.0KB
Capital/Financing Update
2020-02-17 English
Section 708 Certificate 2 pages 252.2KB
Share Issue/Capital Change
2020-02-17 English
Termination of Convertible Loan 2 pages 272.9KB
Capital/Financing Update
2020-02-17 English
Pronounced survival benefit in LuPIN interim trial data 4 pages 194.4KB
Regulatory Filings
2020-02-13 English
$8.1M Financing & Re-Set of Capital Structure 3 pages 263.0KB
Capital/Financing Update
2020-02-13 English
Proposed issue of Securities - NOX 5 pages 28.2KB
Capital/Financing Update
2020-02-13 English
Trading Halt 4 pages 475.7KB
Regulatory Filings
2020-02-11 English
LuPIN interim trial data to be presented at ASCO GU 2020 2 pages 256.0KB
Regulatory Filings
2020-02-10 English
Lapsing of Unlisted Options 2 pages 138.3KB
Capital/Financing Update
2020-02-05 English
Noxopharm Dec 2019 Appendix 4C 11 pages 342.1KB
Interim / Quarterly Report Q2 2019
2020-01-30 English
Noxopharm Non-Deal Roadshow Presentation 26 pages 3.5MB
Investor Presentation
2020-01-28 English
Appendix 3B 12 pages 392.6KB
Capital/Financing Update
2020-01-19 English
Becoming a substantial holder for NYR 2 pages 92.0KB
Major Shareholding Notification
2020-01-15 English
Listing of Nyrada Inc. spin-off on ASX 3 pages 200.6KB
Capital/Financing Update
2020-01-15 English
Noxopharm Corporate Presentation 15 pages 1.0MB
Investor Presentation
2020-01-14 English